First Paper Shows Consistent and Synergic Preclinical Data for PXT-3003 in Two Different CMT 1A Rodent Models Second Paper Presents Positive Phase 2 results of PXT-3003 in 80 Patients with Mild to Moderate CMT 1A Phase 3 Clinical Trial of PXT-3003 in CMT1A set to begin in 2015 PARIS, December 18th, 2014 – Pharnext SAS […]
↧